Regulatory FDA delays decision on Sanofi’s subcutaneous Sarclisa PharmaphorumThe FDA has extended its review of a new version of Sanofi's multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.RegulatoryOncologyRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: MSD-backed Ray locks in $125m to back eye drug pipelineNext: Lilly exits Rigel alliance, adding to RIPK1 scrap heap Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
